ProfileGDS5678 / 1426927_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 65% 65% 65% 65% 68% 66% 65% 65% 65% 65% 65% 65% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9340865
GSM967853U87-EV human glioblastoma xenograft - Control 23.9315665
GSM967854U87-EV human glioblastoma xenograft - Control 33.9358665
GSM967855U87-EV human glioblastoma xenograft - Control 43.9065665
GSM967856U87-EV human glioblastoma xenograft - Control 53.8707965
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1908668
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.037566
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9121765
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8890165
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9156165
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9218165
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8921665
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.924565
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9205965